Los Alamos National Laboratory
We are working with the Hlavacek lab to develop a computational model of autophagy. This team science project involves an iterative process between biologists in the MacKeigan Lab and mathematicians at LANL. The goal for this model is to generate new, non-intuitive predictions about cancer cell behavior, which could inform new therapeutic approaches. This work is funded by the National Cancer Institute, award R01CA197398.
Through a collaboration with Spectrum Health neuro-oncologist, Dr. Sherman, we are using genomic sequencing and computational approaches to analyze mutations and cell types in glioblastoma (GBM) patient tumors. Our research aims to fully characterize the role of neuroinflammation in GBM, which may uncover new targets to be explored as possible therapeutic strategies.
Cincinnati Children’s Hospital Medical Center
Dr. Krueger is an expert TSC clinician and researcher, and we are working with him to sequence TSC patient samples and analyze the resulting genomic data. TSC affects each patient differently, with some patients being symptom-free and others experiencing severe tumor burden and clinical manifestations. This research with Dr. Krueger’s team will determine whether genomic data can explain varying levels of disease severity in patients, and may inform personalized treatment strategies.
Michigan State University
In partnership with Dr. Sortwell, we are investigating the potential of Rho kinase inhibitors as a treatment for Parkinson’s Disease (PD). Dr. Sortwell’s lab has significant expertise using preclinical models of PD, while our team brings strong skills in kinase assays to validate target engagement. This project aims to uncover whether existing drugs or compounds may be repurposed for treatment in PD.